NZ594937A - Beloxepin, its enantiomers, and analogs thereof for the treatment of pain - Google Patents
Beloxepin, its enantiomers, and analogs thereof for the treatment of painInfo
- Publication number
- NZ594937A NZ594937A NZ594937A NZ59493709A NZ594937A NZ 594937 A NZ594937 A NZ 594937A NZ 594937 A NZ594937 A NZ 594937A NZ 59493709 A NZ59493709 A NZ 59493709A NZ 594937 A NZ594937 A NZ 594937A
- Authority
- NZ
- New Zealand
- Prior art keywords
- beloxepin
- pain
- enantiomers
- analogs
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Disclosed is beloxepin enriched in the (-) enantiomer for treating pain, depression, obsessive-compulsive disorder, anorexia nervosa, bulimia nervosa, trichotilomania, insomnia related to opioid withdrawal, and attention deficit hyperactivity disorder and pre-menstral syndrome or dysphoria and fibromyalgia.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2991608P | 2008-02-19 | 2008-02-19 | |
US2991508P | 2008-02-19 | 2008-02-19 | |
US2991308P | 2008-02-19 | 2008-02-19 | |
US5092108P | 2008-05-06 | 2008-05-06 | |
PCT/US2009/034461 WO2009105507A2 (en) | 2008-02-19 | 2009-02-19 | Beloxepin, its enantiomers, and analogs thereof for the treatment of pain |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ594937A true NZ594937A (en) | 2013-03-28 |
Family
ID=40986169
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ587896A NZ587896A (en) | 2008-02-19 | 2009-02-19 | Enantiomers of beloxepin, and the use of beloxepin and its enantiomers to treat pain and other disorders |
NZ594937A NZ594937A (en) | 2008-02-19 | 2009-02-19 | Beloxepin, its enantiomers, and analogs thereof for the treatment of pain |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ587896A NZ587896A (en) | 2008-02-19 | 2009-02-19 | Enantiomers of beloxepin, and the use of beloxepin and its enantiomers to treat pain and other disorders |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2285818A4 (en) |
JP (1) | JP2011512414A (en) |
KR (1) | KR20100137473A (en) |
CN (1) | CN102007139A (en) |
AU (1) | AU2009215541A1 (en) |
BR (1) | BRPI0908098A2 (en) |
CA (1) | CA2715192A1 (en) |
IL (1) | IL207668A0 (en) |
MX (1) | MX2010009110A (en) |
NZ (2) | NZ587896A (en) |
WO (1) | WO2009105507A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090233959A1 (en) | 2008-02-19 | 2009-09-17 | Adolor Corporation | Beloxepin and analogs for the treatment of pain |
KR102385665B1 (en) * | 2015-02-25 | 2022-04-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 5HT agonists to treat disease |
CN106243096B (en) * | 2016-07-29 | 2019-11-29 | 上海璃道医药科技有限公司 | The new application of tricyclic drugs |
US10966938B2 (en) | 2019-01-04 | 2021-04-06 | Jonand4, Llc | Composition and method for preventing or treating hangover symptoms |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE62754B1 (en) | 1988-08-26 | 1995-02-22 | Akzo Nv | Tetracyclic antidepressants |
US5663178A (en) | 1995-02-06 | 1997-09-02 | Eli Lilly And Company | Tetrahydro-beta carbolines |
TW440563B (en) * | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
US5952331A (en) | 1996-05-23 | 1999-09-14 | Syntex (Usa) Inc. | Aryl pyrimidine derivatives |
GB0004003D0 (en) * | 2000-02-22 | 2000-04-12 | Knoll Ag | Therapeutic agents |
GB0019950D0 (en) | 2000-08-12 | 2000-09-27 | Smithkline Beecham Plc | Compounds |
KR20050085538A (en) * | 2002-12-11 | 2005-08-29 | 파마시아 앤드 업존 캄파니 엘엘씨 | Combination for the treatment of adhd |
MXPA06005019A (en) * | 2003-11-03 | 2006-07-06 | Warner Lambert Co | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders. |
CA2588595A1 (en) * | 2004-12-13 | 2006-06-22 | Arena Pharmaceuticals, Inc. | N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto |
NZ556272A (en) * | 2005-01-27 | 2009-12-24 | Janssen Pharmaceutica Nv | Heterocyclic tetracyclic tetrahydrofuran derivatives as 5HT2 inhibitors in the treatment of CNS disorders |
WO2006105117A2 (en) * | 2005-03-28 | 2006-10-05 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
JP2009510095A (en) * | 2005-09-29 | 2009-03-12 | ワイス | Benzothiadiazoliphenylalkylamine derivatives for use in the treatment of symptoms ameliorated by monoamine reuptake |
CA2647835A1 (en) * | 2006-03-28 | 2007-10-04 | Neopro Labs, Llc | Methods and compositions for treating conditions |
GB0608655D0 (en) * | 2006-05-03 | 2006-06-14 | Merck Sharp & Dohme | Therapeutic Treatment |
US20070281924A1 (en) * | 2006-05-31 | 2007-12-06 | Gaeta Federico C | MIF inhibitors for treating neuropathic pain and associated syndromes |
-
2009
- 2009-02-19 KR KR1020107021010A patent/KR20100137473A/en not_active Application Discontinuation
- 2009-02-19 BR BRPI0908098-8A patent/BRPI0908098A2/en not_active IP Right Cessation
- 2009-02-19 AU AU2009215541A patent/AU2009215541A1/en not_active Abandoned
- 2009-02-19 WO PCT/US2009/034461 patent/WO2009105507A2/en active Application Filing
- 2009-02-19 NZ NZ587896A patent/NZ587896A/en not_active IP Right Cessation
- 2009-02-19 MX MX2010009110A patent/MX2010009110A/en not_active Application Discontinuation
- 2009-02-19 EP EP09712730A patent/EP2285818A4/en not_active Withdrawn
- 2009-02-19 JP JP2010547737A patent/JP2011512414A/en not_active Withdrawn
- 2009-02-19 CN CN2009801138213A patent/CN102007139A/en active Pending
- 2009-02-19 NZ NZ594937A patent/NZ594937A/en not_active Application Discontinuation
- 2009-02-19 CA CA2715192A patent/CA2715192A1/en not_active Abandoned
-
2010
- 2010-08-18 IL IL207668A patent/IL207668A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2009215541A1 (en) | 2009-08-27 |
NZ587896A (en) | 2011-09-30 |
WO2009105507A2 (en) | 2009-08-27 |
CN102007139A (en) | 2011-04-06 |
EP2285818A2 (en) | 2011-02-23 |
JP2011512414A (en) | 2011-04-21 |
MX2010009110A (en) | 2010-11-30 |
EP2285818A4 (en) | 2011-08-17 |
CA2715192A1 (en) | 2009-08-27 |
BRPI0908098A2 (en) | 2015-08-18 |
KR20100137473A (en) | 2010-12-30 |
IL207668A0 (en) | 2010-12-30 |
WO2009105507A3 (en) | 2010-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201100748A1 (en) | PYRAZINE COMPOUNDS AS PHOSPHODESTERASE INHIBITORS 10 | |
DE602008004245D1 (en) | IMPROVED METHOD FOR THE PRODUCTION OF 6-ALPHA-HYDROXY-N-ALKYLATED OPIATES | |
MX2012000150A (en) | Biological methods for preparing adipic acid. | |
TN2012000549A1 (en) | Substituted 5-fluoro-1h-pyrazolopyridines and use thereof | |
UA102065C2 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | |
MY156777A (en) | Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof | |
MY178338A (en) | Compositions and methods for biological production of lactate from c1 compounds using lactate dehydrogenase transformants | |
MX2011009369A (en) | Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators. | |
MX2010006033A (en) | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof. | |
NZ594937A (en) | Beloxepin, its enantiomers, and analogs thereof for the treatment of pain | |
ATE447593T1 (en) | LOW VISCOSE POLYADDITION COMPOUNDS CONTAINING URETDIONE GROUPS, METHOD FOR PRODUCTION AND USE | |
MX351133B (en) | Method for treating osteoporosis. | |
MX2012000583A (en) | Method for producing chiral 3-triazolyl-sulfoxide derivatives. | |
IN2015DN01811A (en) | ||
MY158569A (en) | Treatment of biofuels | |
UA102238C2 (en) | 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof | |
MX2009009362A (en) | Novel dosage form. | |
MX337526B (en) | Processes for the manufacture of macrocyclic depsipeptides and new intermediates. | |
BR112014002859A2 (en) | post-processing purification for production of lactone gamma-butyr | |
MY170615A (en) | Novel matting agent for uv varnishes | |
WO2010028207A9 (en) | Method of treatment of attention deficit/hyperactivity disorder (adhd) | |
MX2015000401A (en) | Process for the production of methylbutinol. | |
MX2010009931A (en) | Process for the preparation of 2-amino-2- [2- (4-c3-c21-alkyl-phenyl)ethyl] propane-1, 3-diols. | |
MX2010004998A (en) | Catenate for immunostimulation. | |
MX2011012507A (en) | Substituted piperidines. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ERR | Error or correction |
Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: BELOXEPIN, ITS ENANTIOMERS, AND ANALOGS THEREOF FOR THE TREATMENT OF PAIN; FILING DATE: 31 AUG 2011; STATUS: REJECTED; PUBLICATION DATE: 28 MAR 2013; Effective date: 20130408 |
|
AABA | Application abandoned |